SummitTX Capital’s Nuvation Bio NUVB Stock Holding History

SummitTX Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-578,304	Closed	-$5.18M	–	910
2025 Q4	$5.18M	Buy	+578,304	New	+$3.58M	0.16%	152

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SummitTX Capital's NUVB Position: Q1 2026 in Review

SummitTX Capital sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 578,304 shares — an estimated $5.18M sold.

SummitTX Capital first reported a position in NUVB in Q4 2025 and held it in 1 quarter. The position peaked at $5.18M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

SummitTX Capital reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 578,304 Nuvation Bio shares in Q1 2026, an estimated $5.18M.
SummitTX Capital first reported a position in Nuvation Bio in Q4 2025 and held it in 1 quarter.
SummitTX Capital's Nuvation Bio position peaked at $5.18M in Q4 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.